FATE - Fate Therapeutics jumps 9% after ASH presentation attracts attention

Fate Therapeutics (FATE) trades higher after a presentation over the weekend at the ASH conference on FT516 data. "Given the heavily pretreated nature of these patients, we believe FT516 played a dominant role in the combination’s activity, further de-risking iNK cells as a therapeutic modality. In our view, these data showcase the therapeutic potential of Fate's PSC-NK pipeline, and will likely attract additional investor interest," updates Oppenheimer analyst Matthew Biegler. The firm keeps an Outperform rating on Fate and boosts its price target to $70 from $60. Shares of FATE are up 8.55% in premarket trading.

For further details see:

Fate Therapeutics jumps 9% after ASH presentation attracts attention